BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38520216)

  • 1. Histone modification-linked prognostic model for ovarian cancer reveals LBX2 as a novel growth promoter.
    Xiong J; Liang H; Sun X; Gao K
    J Cell Mol Med; 2024 Apr; 28(8):e18260. PubMed ID: 38520216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel immune-related gene signature for risk stratification and prognosis prediction in ovarian cancer.
    Fei H; Han X; Wang Y; Li S
    J Ovarian Res; 2023 Oct; 16(1):205. PubMed ID: 37858138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crosstalk of RNA Adenosine Modification-Related Subtypes, Establishment of a Prognostic Model, and Immune Infiltration Characteristics in Ovarian Cancer.
    Ni X; Chen C; Cui G; Ding W; Liu J
    Front Immunol; 2022; 13():932876. PubMed ID: 35837397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycosylation-related genes mediated prognostic signature contribute to prognostic prediction and treatment options in ovarian cancer: based on bulk and single‑cell RNA sequencing data.
    You Y; Yang Q
    BMC Cancer; 2024 Feb; 24(1):207. PubMed ID: 38355446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer.
    Jiao J; Jiang L; Luo Y
    Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer.
    Liu J; Liu Y; Yang C; Liu J; Hao J
    Transl Oncol; 2023 Nov; 37():101762. PubMed ID: 37619523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of an Autophagy-Related Signature for Prognosis and Immunotherapy Response Prediction in Ovarian Cancer.
    Ding J; Wang C; Sun Y; Guo J; Liu S; Cheng Z
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian cancer subtypes based on the regulatory genes of RNA modifications: Novel prediction model of prognosis.
    Zheng P; Li N; Zhan X
    Front Endocrinol (Lausanne); 2022; 13():972341. PubMed ID: 36545327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
    Zhao Q; Fan C
    BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq.
    Zhang D; Lu W; Cui S; Mei H; Wu X; Zhuo Z
    J Ovarian Res; 2022 Nov; 15(1):123. PubMed ID: 36424614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a five-gene signature as a novel prognostic marker in ovarian cancer.
    Wang R; Ye XH; Zhao XL; Liu JL; Zhang CY
    Neoplasma; 2019 May; 66(3):343-349. PubMed ID: 30569721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of a Hypoxia-related Prognostic Model for Ovarian Cancer.
    Xie L; Pan M; Zhang Z; Jiang X; Chen Y; Liu G; Chen Y; Zeng Y; Guan J; Lu R; Zeng L
    Recent Pat Anticancer Drug Discov; 2022; 18(2):161-173. PubMed ID: 35747984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coordinating single-cell and bulk RNA-seq in deciphering the intratumoral immune landscape and prognostic stratification of prostate cancer patients.
    Sun Z; Wang J; Zhang Q; Meng X; Ma Z; Niu J; Guo R; Tran LJ; Zhang J; Liu Y; Ye F; Ma B
    Environ Toxicol; 2024 Feb; 39(2):657-668. PubMed ID: 37565774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ELK1 activated-long noncoding RNA LBX2-AS1 aggravates the progression of ovarian cancer through targeting miR-4784/KDM5C axis.
    Gu H; Lin R; Zheng F; Zhang Q
    J Mol Histol; 2021 Feb; 52(1):31-44. PubMed ID: 33099720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenic cell death-related gene landscape predicts the overall survival and immune infiltration status of ovarian cancer.
    Zhang W; Liu T; Jiang L; Chen J; Li Q; Wang J
    Front Genet; 2022; 13():1001239. PubMed ID: 36425071
    [No Abstract]   [Full Text] [Related]  

  • 16. An immune-related exosome signature predicts the prognosis and immunotherapy response in ovarian cancer.
    Zhu K; Ma J; Tian Y; Liu Q; Zhang J
    BMC Womens Health; 2024 Jan; 24(1):49. PubMed ID: 38238671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of scRNA-Seq and Bulk RNA-Seq to Analyse the Heterogeneity of Ovarian Cancer Immune Cells and Establish a Molecular Risk Model.
    Liang L; Yu J; Li J; Li N; Liu J; Xiu L; Zeng J; Wang T; Wu L
    Front Oncol; 2021; 11():711020. PubMed ID: 34621670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-omics approaches establishing histone modification based prognostic model in glioma patients and further verification of the carcinogenesis mechanism.
    Wang Y; Ji L; Ji C; Wang F
    Funct Integr Genomics; 2023 Sep; 23(4):307. PubMed ID: 37730879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative Stress Response Biomarkers of Ovarian Cancer Based on Single-Cell and Bulk RNA Sequencing.
    Zheng M; Hu Y; Liu O; Li S; Wang Y; Li X; Liu J; Yang Q; Li X; Lin B
    Oxid Med Cell Longev; 2023; 2023():1261039. PubMed ID: 36743693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective pathway signaling and prognostic values of MicroRNA-9 in ovarian cancer based on gene expression omnibus (GEO): a bioinformatics analysis.
    Zuo L; Li X; Tan Y; Zhu H; Xiao M
    J Ovarian Res; 2021 Feb; 14(1):29. PubMed ID: 33563317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.